A detailed history of State Of Wisconsin Investment Board transactions in 89bio, Inc. stock. As of the latest transaction made, State Of Wisconsin Investment Board holds 140,245 shares of ETNB stock, worth $1.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
140,245
Previous 154,522 9.24%
Holding current value
$1.26 Million
Previous $1.24 Million 16.17%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.36 - $9.66 $105,078 - $137,915
-14,277 Reduced 9.24%
140,245 $1.04 Million
Q2 2024

Aug 14, 2024

BUY
$7.31 - $10.9 $261,456 - $389,860
35,767 Added 30.12%
154,522 $1.24 Million
Q1 2024

May 14, 2024

SELL
$8.13 - $13.77 $25,268 - $42,797
-3,108 Reduced 2.55%
118,755 $1.38 Million
Q4 2023

Feb 12, 2024

SELL
$6.66 - $16.03 $27,365 - $65,867
-4,109 Reduced 3.26%
121,863 $1.36 Million
Q3 2023

Nov 14, 2023

SELL
$15.06 - $19.41 $72,408 - $93,323
-4,808 Reduced 3.68%
125,972 $1.95 Million
Q2 2023

Aug 14, 2023

BUY
$14.15 - $22.03 $726,347 - $1.13 Million
51,332 Added 64.61%
130,780 $2.48 Million
Q3 2022

Nov 14, 2022

SELL
$3.02 - $7.0 $177,576 - $411,600
-58,800 Reduced 42.53%
79,448 $460,000
Q2 2022

Aug 15, 2022

BUY
$2.09 - $4.02 $37,571 - $72,267
17,977 Added 14.95%
138,248 $445,000
Q1 2022

May 13, 2022

BUY
$3.45 - $14.99 $247,365 - $1.07 Million
71,700 Added 147.62%
120,271 $453,000
Q2 2021

Aug 12, 2021

SELL
$17.42 - $28.0 $160,264 - $257,600
-9,200 Reduced 15.92%
48,571 $908,000
Q4 2020

Feb 03, 2021

BUY
$23.16 - $28.08 $1.34 Million - $1.62 Million
57,771 New
57,771 $1.41 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $417M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track State Of Wisconsin Investment Board Portfolio

Follow State Of Wisconsin Investment Board and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wisconsin Investment Board with notifications on news.